logo
Experts pinpoint exactly how long you need to use a contraceptive pill to increase your risk of a brain tumour

Experts pinpoint exactly how long you need to use a contraceptive pill to increase your risk of a brain tumour

Daily Mail​a day ago

Millions of women taking the mini-pill could be at increased risk of developing a brain tumour, new research suggests.
Experts found that women taking the progestogen-only pill—often dubbed 'the mini-pill' continuously for more than five years were more likely to develop a meningioma.
Meningiomas accounts for a third of all brain tumours diagnosed in the UK each year.
While usually non-cancerous they can still cause problems they grow larger inside the brain.
In the new study, French researchers analysed data from over 8,000 women, with an average age of 60, who had surgery for this form of tumour.
They found women who did were more likely to have been taking the mini pill—medically called desogestrel for at least five years.
However, independent experts have said women on the medication shouldn't panic, as the increased risk is relatively small.
Desogestrel, in contrast to the more famous Pill, only contains one sex hormone progestogen.
It is primarily taken by women with underlying health conditions that makes taking other contraceptives dangerous, or who suffer adverse side effects when doing so.
The NHS says natural family planning can be up to 99 per cent effective when done correctly and around 75 per cent if not used according to instructions. By comparison, the Pill, implant, IUS and IUD are 99 per cent effective with perfect use, while condoms are 98 per cent
While the increased risk of a meningioma was observed, the authors—who published their findings in the British Medical Journal —said it was relatively minor.
They outlined that only one out of 67,000 women taking desogestrel will develop a meningioma requiring surgery.
The scientists also found that there was no increased risk when the mini pill was used for less than five years.
They also found that the increased risk disappeared a year after coming off the mini pill.
Meningiomas are a tumour of the membrane that surrounds the brain, with more than 90 per cent of these are not cancerous.
While not at risk of spreading elsewhere in the body like a cancerous growth they can still cause patients problems.
Every year proportion of meningioma patients will need surgery to remove the tumour due to it causing increased internal pressure on the brain.
Common symptoms of a meningioma include a persistent headache as well as constant nausea which is often accompanied with drowsiness.
Dr Mangesh Thorat, an expert in population health at Queen Mary University of London, who was not involved in the study, said women on the medication shouldn't be alarmed.
'The magnitude of increase in the risk is small, and short-term use is not associated with increased risk and that the excess risk ceases to exist once the use is stopped for more than a year,' he said.
He advised women who may be concerned about their risk to contact their GP.
'Talk to your healthcare provider regarding the drug you are using. If it is associated with an increased risk of meningioma, this can be changed to a safer alternative,' he said.
Experts say that a limitation of the study is that the researchers only looked at one type of progestogen pill—desogestrel and not other drugs that also include the hormone.
Dr Thorat said: 'the study cannot provide information on the formulations not commonly used in France but used in other countries.'
He has called on further studies to be undertaken in different countries.
Figures currently suggest around 6 per cent of women aged 16 to 49 use the mini pill in the UK—roughly 3.1 million patients.
Taken every day, it works by thickening cervical mucus and thinning the womb lining which helps stop sperm reaching an egg and from a fertilised egg attaching itself in the womb.
In some cases, the mini pill can also stop ovulation from occurring.
It is 99.7 per cent effective with perfect use but if used incorrectly—such as missing a pill or experiencing nausea and diarrhoea while on it—around one in ten women (9 per cent) may get pregnant.
Known side effects of the mini pill—proven to be over 99 per cent effective at stopping pregnancy—include nausea, breast tenderness, mood swings and headaches.
Others claim they pile on pounds while taking the drug because of increased fluid retention and appetite.
However, the NHS says there is no evidence it leads to weight gain.
The latest study comes just a month after British scientists found that women with asthma who are taking the mini pill were a third more likely to suffer an attack.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Women's Prize for Fiction ‘greatest honour' as an intersex woman, says winner
Women's Prize for Fiction ‘greatest honour' as an intersex woman, says winner

The Independent

time28 minutes ago

  • The Independent

Women's Prize for Fiction ‘greatest honour' as an intersex woman, says winner

The winner of the Women's Prize for Fiction has said the award is 'the greatest honour of my life as a woman' as she reflected on her experience growing up intersex. Dutch author Yael van der Wouden won the accolade for her debut novel, The Safekeep, and used her winner's speech to champion the trans community, who have 'changed the system' and 'fought for health care'. The book, which explores repressed desire and the unresolved aftermath of the Holocaust in post-Second World War Netherlands, was described as an 'astonishing debut' by the head of the judges. The ceremony, held in central London on Thursday, saw the non-fiction prize awarded to physician Dr Rachel Clarke for The Story Of A Heart, which explores the human experience behind organ donation. In her winner's speech, after thanking the judges, van der Wouden said: 'I was a girl until I turned 13, and then, as I hit puberty, all that was supposed to happen did not quite happen. 'And if it did happen, it happened too much, and all at once my girlhood became an uncertain fact. 'I won't thrill you too much with the specifics, but the long and the short of it is that, hormonally, I'm intersex. 'This little fact defined my life throughout my teens, until I advocated for the health care that I needed. 'The surgery and the hormones that I needed, which not all intersex people need. Not all intersex people feel at odds with their gender presentation. 'I mention the fact that I did, because in the few precious moments here on stage, I am receiving, truly, the greatest honour of my life as a woman, presenting to you as a woman, and accepting this Women's Prize. 'And that is because of every single trans person who's fought for health care, who changed the system, the law, societal standards, themselves. I stand on their shoulders.' The NHS website says intersex, or differences in sex development (DSD), is a group of rare conditions involving genes, hormones and reproductive organs that mean a person's sex development is different to most. In contrast, people who are transgender identify as a gender separate to the sex they were born in and sometimes go through gender-affirming surgery. Van der Wouden's novel follows Isabel, a young woman whose life in solitude is upended when her brother's girlfriend Eva comes to live in their family house in what turns into a summer of obsession, suspicion and desire. The chairwoman of the judges for the fiction prize, writer Kit de Waal, said: 'This astonishing debut is a classic in the making, a story to be loved and appreciated for generations to come. Books like this don't come along every day.' Van der Wouden will receive £30,000 and a limited-edition bronze statuette known as the Bessie, which was created and donated by artist Grizel Niven. The judging panel for the Women's Prize for Fiction included novelist and journalist Diana Evans, author and journalist Bryony Gordon, writer and magazine editor Deborah Joseph, and musician and composer Amelia Warner. Clarke said she has 'literally been a feminist since I was too young to know what that word even meant', as she collected her award. The physician's book recounts two family stories, documenting how medical staff take care of nine-year-old Kiera in her final hours after a car accident, while offering a new life to nine-year-old Max who is suffering from heart failure from a viral infection. Clarke, who is behind the books Breathtaking and Your Life In My Hands: A Junior Doctor's Story, will receive £30,000 and a limited-edition piece of art known as the Charlotte, both gifted by the Charlotte Aitken Trust. The judging panel for the non-fiction prize included writer and broadcaster Dr Leah Broad, whose work focuses on women's cultural history, and novelist and critic Elizabeth Buchan. Previous winners of the fiction prize include Tayari Jones for An American Marriage and Madeline Miller for The Song Of Achilles, while the first non-fiction prize was awarded last year to Naomi Klein for Doppelganger: A Trip Into The Mirror World. The awards were announced by the Women's Prize Trust, a UK charity that aims to 'create equitable opportunities for women in the world of books and beyond'.

Parents whose sons are losing ability to walk face ‘nightmare' battle with NHS
Parents whose sons are losing ability to walk face ‘nightmare' battle with NHS

Western Telegraph

timean hour ago

  • Western Telegraph

Parents whose sons are losing ability to walk face ‘nightmare' battle with NHS

The medicine givinostat can slow progress of Duchenne muscular dystrophy – keeping children on their feet for longer – and is being offered for free by a drug firm while it goes through the process of NHS approval. However, only some NHS trusts across the UK, and few in England, are giving the drug despite it being part of an early access programme since November. Families are now facing a 'cruel' postcode lottery over who gets the medicine and are in a race against time, according to the charity Duchenne UK. Some NHS trusts are refusing to supply the drug while others delay it by drawing up lists of who they think should get it first. NHS trusts say they need to pay for monitoring the drug – around £1,900 per year per patient – out of their own budget. In desperation, parents have met with Health Secretary Wes Streeting to try and speed up access. According to the Government, it is up to individual NHS trusts to decide whether to provide the drug. Duchenne UK is supporting families in their fight for givinostat, including Rosie and Pete Day, an investment manager, and their 10-year-old son Jasper, from Horsham, West Sussex. The Day family have twins Jasper and Arabella, aged 10, and two older daughters. Jasper enjoys a range of hobbies (Family handout/PA) Both Jasper and Arabella have Duchenne, with Arabella a carrier of the genetic disorder and Jasper the most affected, as the condition mostly affects boys. The drug, developed by ITF Pharma UK, is only being given under the early access programme to children who are still able to walk. Mrs Day told the PA news agency: 'We try and live in the moment and, in this moment, there's an opportunity to make a massive change to Jasper. 'We're not going to cure it, but this drug gives him the best chance of having the early life that he wants to have and what every parent wants to give their child. 'It's so close – and yet we're stuck. 'We're stuck in this process where there's something in reaching distance that could make a huge difference to keep him walking, keep him active, keep him with his siblings in the garden, keep him walking up the stairs, all of those things, and it just feels that we can't quite get there. 'We're on the finishing line to get something that will make a difference and we can't quite get there because of the system we're in. 'The drug is not going to cure it, but it will give him the childhood you would wish to give your child – to keep them playing football, coming on dog walks, being able to walk up the stairs, playing the French horn, all of those things that you dream your child is going to get to do. 'We can't give it because it we're stuck, even though it's free and it's there – we can't give it. 'It feels like a nightmare, because you know that the doctors want to give it, but when it comes to getting the drug in his mouth and seeing what it would do, we're stuck. 'It's a lottery, basically, depending on where you are in the country … and within NHS trusts themselves.' Jasper is under the care of the Evelina London Children's Hospital, which is only now starting to contact patients and is drawing up a priority list for who gets the drug first. 'Every day that passes by is a day that we can see Jasper decline and see him struggling with his muscles,' Mrs Day said. 'Two weeks ago, he asked me, 'When will I get the drug, mummy?' 'We're stuck in a situation over who's going to make those decisions regarding who gets the drug – of whether Jasper gets it or another boy. 'For every boy it's heartbreaking, because someone ultimately is not going to get the drug at that moment based on the current criteria.' She added: 'If Jasper stops walking, we're not going to get that back. 'Every day matters. Six months ago, Jasper could walk up and down the stairs easily. He can't do that now and Pete has to push him up the stairs every night. 'Yet we can't give him something that is as simple as two spoons full of medicine and a blood test, and a little bit of maybe resource looking at the blood test results – that is what is standing in our way.' Mrs Day said it was unclear how the Evelina is 'going to make a fair choice' because knowing who will lose mobility is not an exact science. Mr Day said the process is 'hugely subjective' because there is no linear decline in the condition and the decisions made by NHS trusts could end up being 'completely wrong'. According to Duchene UK, boys whose condition is getting worse risk falling off the list entirely while waiting for the drug. Around 500 boys in the UK are eligible for givinostat, which can be taken at home like Calpol, with hospitals then doing follow-up blood tests of around eight in the first year, followed by twice a year thereafter. Children may also need an ECG, though these are already part of routine Duchenne monitoring. Emily Reuben and Alex Johnson, founders of Duchenne UK, said: 'As time ticks by, more boys are losing out on their chance to access givinostat. 'This is a simple treatment, which can be easily managed at home, and requires uncomplicated blood tests to monitor. It's free to the NHS and could offer real hope for patients and their families. 'The delays are cruel and the postcode lottery is unjustifiable. We are calling on the NHS to urgently make this available to both ambulant (walking) and non-ambulant boys.' To date, all health boards in Scotland are rolling out the drug, alongside those in Swansea and Cardiff. Leicester Royal Infirmary was the first trust in England to give the drug, but the Evelina has not yet, and neither have trusts in Manchester, Liverpool and Newcastle. Great Ormond Street Hospital is working to supply the drug. A spokesman for the Evelina said: 'We have begun contacting families of all existing Evelina London patients who may be eligible for givinostat and are working to set up appointments in the next few months. 'Our clinical team are working through our patient lists and are currently prioritising children who need the treatment most urgently, or are at a higher risk of losing movement (ambulation) soon.' An NHS spokesman said: 'The first National Institute for Health and Care Excellence (Nice) committee meeting to consider this treatment is scheduled to be held in July 2025, and if manufacturer ITF Pharma can offer a cost-effective price to enable Nice to recommend its use, the NHS will be ready to work with the company to explore fast-tracking access for patients. 'NHS England has published guidance on manufacturer-led early access schemes, which require trusts to cover substantial costs and find additional clinical resources to administer new treatments, and we understand a number of trusts across the country are preparing to offer givinostat via such a scheme.'

‘Trojan horse' treatment given green light for NHS use
‘Trojan horse' treatment given green light for NHS use

Western Telegraph

timean hour ago

  • Western Telegraph

‘Trojan horse' treatment given green light for NHS use

The targeted therapy can stop myeloma from progressing by nearly three times as long as existing treatments, studies suggest. It is estimated that around 1,500 patients a year with multiple myeloma – an incurable cancer of the bone marrow – will benefit from the treatment. Paul Silvester received his treatment at the Royal Hallamshire Hospital in Sheffield (handout/PA) It comes after the National Institute for Health and Care Excellence (Nice) approved belantamab mafodotin, also known as Blenrep and made by GlaxoSmithKline, for NHS use. NHS England said that it is the first health system in the world to roll out the treatment. Officials said that the drug can now be offered to patients whose cancer has progressed or not responded to another first-line treatment. The treatment, which is given as an infusion every three weeks along with other cancer drugs, is a type of antibody drug which targets and attaches to cancer cells. It has been dubbed a 'Trojan horse' treatment because it works by being taken into a cancer cell, before releasing a high concentration of a lethal molecule to destroy the cell from inside. 'Myeloma is an aggressive type of blood cancer, but we have seen a steady improvement in the outlook for patients over recent years as we have introduced new targeted therapies,' Professor Peter Johnson, NHS England's national clinical director for cancer, said. 'I am delighted that patients in England will be the first to benefit from this new treatment, which has the potential to keep cancer at bay for years longer, giving people the chance of more precious time with friends and family. 'This treatment could be life-changing for many patients and their families, and that's why it is so important that the NHS continues to secure quick access to the latest, innovative treatments like this, at affordable prices to the taxpayer.' 🚨 Do you know the key symptoms of #myeloma? 🚨 Help us spread the word by sharing this post! Early diagnosis makes all the difference. If something feels off, don't wait – talk to your GP!#BloodCancerAwarenessMonth @MyelomaUK — DKMS UK | We Delete Blood Cancer (@DKMS_uk) September 6, 2024 Helen Knight, director of medicines evaluation at Nice, said: 'We're delighted that people in the UK will become among the first in the world to access belantamab mafodotin for this indication. 'This recommendation demonstrates our commitment to getting the best care to patients fast, while ensuring value for the taxpayer.' Trials have suggested that the treatment, in combination with bortezomib and dexamethasone, delayed progression of the disease by an average of three years, compared to just over a year for patients taking commonly-used drug daratumumab along with the other treatments. Patient Paul Silvester, 60, from Sheffield, was diagnosed with myeloma in July 2023 and received treatment at the Royal Hallamshire Hospital. The first treatment he was given failed to stop his cancer from progressing so he was given belantamab mafodotin through an early access programme. 'I feel like this treatment has brought the party balloons back in the house. It has been amazing – within the first two or three weeks, after the first dose, I was in remission,' he said. 'It gives me quite a lot of confidence in the drugs and it makes me more optimistic about the future. 'I've been feeling well and I'm still quite active – that's what's important in terms of your quality of life. 'One of my daughters is graduating from university in October and it's a goal for me to be there.' Shelagh McKinlay, director of research and advocacy at blood cancer charity Myeloma UK, said: 'It's fantastic to see the UK at the forefront of myeloma treatment. 'We have been working very hard for the last year to get this treatment approved and we know it will transform the lives of thousands of people with myeloma.' Health Minister Karin Smyth said: 'This groundbreaking therapy puts the NHS at the forefront of cancer innovation. 'By harnessing cutting-edge 'trojan horse' technology, we're offering new hope to blood cancer patients across the country.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store